Skip to content

Clinical trials

Phase 2/3 trials in Belarus

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 2/3 Country / region: Belarus Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20101
20131
20151
20163
20173
20181
20191
20202
20241
20254

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed6
Recruiting5
Terminated3
Unknown status3
Active, not recruiting1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Medecins Sans Frontieres, Netherlands3
N.N. Alexandrov National Cancer Centre2
Research Institute for Physical Chemical Problems of the Belarusian State University2
AVVA Pharmaceuticals Ltd.1
AbbVie1
Belarusian Medical Academy of Post-Graduate Education1
Biocad1
Janssen Research & Development, LLC1
Mateon Therapeutics1
Nabriva Therapeutics AG1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Extensively Drug-Resistant Tuberculosis3
Tuberculosis, Multidrug-Resistant3
Tuberculosis, Pulmonary3
Crohn Disease2
Arthritis, Rheumatoid1
Candidiasis, Vulvovaginal1
Carcinoma, Non-Small-Cell Lung1
Colitis, Ulcerative1
Common Variable Immunodeficiency1
Fallopian Tube Neoplasms1

Trials

Showing 76 to 19 of 19. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.